New 'Pan-Cancer' analysis reveals the common roots of different cancers

April 5, 2018, University of California - Santa Cruz
The UCSC Tumor Map helps researchers visualize the dominant patterns found in the TCGA data, such as the cell of origin, molecular histology, 'stemness' or differentiation status, specific altered genetic pathways, and the immune system component of the tumors. Credit: UC Santa Cruz Genomics Institute

Typically cancers are classified by where they originate in the body—think breast cancer, stomach cancer, and so on. But a collaboration called the Pan-Cancer Initiative, launched in 2012 at a meeting in Santa Cruz, California, sought to study cancers from a new angle—a molecular one. Preliminary analyses showed cancers that start in different organs actually share commonalities at the molecular level, whereas cancers that originate from the same tissue can have very different genomic profiles.

Now, the Pan-Cancer Initiative has released the results of a much larger analysis of genomic and molecular data characterizing 33 different types of from more than 10,000 patients. Called the Pan-Cancer Atlas, it is the most comprehensive cross-cancer analysis to date and is the final output of The Cancer Genome Atlas (TCGA) program, a joint effort of the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI). The results appear in 27 papers published April 5 in Cell, Cancer Cell, Cell Reports, and Immunity.

"Insights about how one type of cancer relates to another form of the disease can have real ," said Josh Stuart, Baskin Professor of Biomolecular Engineering at UC Santa Cruz and an organizer of the Pan-Cancer Initiative. "In some cases, we can borrow clinical practices from better-known diseases and apply them to cancers for which treatment options are less well defined."

Stuart's main collaborators on the pan-cancer analyses have been Christopher Benz, professor of cancer and developmental therapeutics at the Buck Institute for Research on Aging and a clinical oncologist at UC San Francisco, and Christina Yau, assistant adjunct professor of surgery at UCSF and a senior scientist at the Buck Institute. Stuart and Benz are co-directors of the UCSC-Buck Institute Genome Data Analysis Center, one of seven national centers in the TCGA Research Network.

Working with an international team of researchers, they performed a comprehensive molecular analysis of the complete set of TCGA tumor data. The results showed that, based on their cellular and genetic makeup and independent of their anatomic site of origin, all 33 tumor types could be re-classified into 28 different molecular types, or "clusters." Nearly two-thirds of these clusters were considered heterogeneous as they contained up to 25 different histological tumor types that, traditionally, would all be treated differently. These molecular analyses and clustering results, now also linked to multiple clinical outcome endpoints, are available to clinicians and researchers worldwide via a single TCGA portal.

"This comprehensive body of final TCGA Pan-Cancer Atlas analyses will provide a new foundation for future cancer research efforts and clinical trials," Benz said. "It will also incentivize clinical oncologists to get newly diagnosed and recurrent tumors genomically characterized. Patients will have the best shot at successful treatment if their tumors can first be classified according to their genomic and molecular makeup."

The first wave of cross-tumor comparisons was completed in September 2013, when Stuart and his colleagues in the Pan-Cancer Initiative analyzed 12 types of tumors profiled by TCGA. While most tumors did end up being grouped by their tissue of origin, there were some common DNA, RNA, and protein signals that cut across those groupings.

"It became clear, when we found similarities between different types of cancer, people wanted to do a more comprehensive comparison," Stuart said.

In 2014, he coauthored another pan-cancer paper in which the researchers sorted the tumors into subtypes, or clusters, using a statistical analysis of tumor molecular data. While a majority of the cancer subtypes matched their tissue-of-origin, some of the clusters consisted of tumors that originated in different parts of the body. The 2014 study indicated that one in 10 cancer patients would be classified differently using the new molecular classifications, and those differences could have ramifications for what types of treatment options or clinical trials should be made available to those patients.

As co-leader of the Pan-Cancer working group for TCGA and the International Cancer Genomics Consortium, Stuart has played an integral role in ensuring the research compiled by the collaboration was organized under one common umbrella and overseen by a single steering committee.

Stuart helped organize the 27 Pan-Cancer Atlas papers published April 5 in Cell Press journals. He said the Pan-Cancer Initiative's work so far resembles a giant tree, with roots representing different means of classifying tumors, and sub-roots branching off each of the main roots. This organizational structure provided the basis for "themed working groups," rather than groups based on organ or tissue type.

Stuart and Benz are senior authors of one of the papers, published in Cell and led by Peter Laird of Van Andel Research Institute, which provides a roadmap for other researchers seeking to delve into the findings of the various working groups. "It's a survey of what kinds of overarching systems underlie the data. It's less about clinical implications, and more about the patterns we've found," Stuart said. The first authors of the paper include Yau and Christopher Wong, a staff scientist in Stuart's lab at the UC Santa Cruz Genomics Institute.

Stuart said he is confident that once scientists start scrutinizing the data, clinical implications won't be far behind. "Obviously, finding actionable pieces of logic from these root maps is the holy grail," he said. "The milestone we hit with this paper is finally being able to stand back and look at the big picture."

The UCSC Tumor Map, an interactive browser developed by Yulia Newton and Adam Novak to help researchers visualize the data, displays patient samples on a Google Maps interface. Wong used the browser to compile a set of 10 panels in the Cell paper illustrating the dominant patterns found in the data. These include the cell of origin, molecular histology, "stemness" or differentiation status, specific altered genetic pathways, and the immune system component of the tumors.

"Looking at these Tumor Maps is like looking at the Earth from orbit for the first time," Stuart said. "We now see cancer's complete picture and it fills me with hope that we can understand its finite, not infinite, complexity."

UC Santa Cruz has a legacy of creating browsers for the biological community, starting with the highly popular UCSC Genome Browser. "We are thrilled to make this rich data available to the public through this new portal," Stuart said.

Benz said the new TCGA data hold particular promise for expanding treatments designed to enlist the immune system to beat cancer, including approved immunotherapies now showing near-miraculous results against a limited number of classical cancer types. Remarkably, the study shows that one of the most heterogeneous of the observed 28 molecular clusters was composed of 25 different classical tumor types and exhibited very strong features linked to activation of the patient's immune response.

"This finding supports the growing notion that specific immunotherapies approved by the FDA for one cancer type would likely benefit patients with various other cancer types, if these other types could be molecularly identified," Benz said.

Drugs approved for other diseases could also be effective against some of the newly classified cancer types. "A couple of our newly defined cancer clusters also show activation of a molecular pathway (JAK/Stat) that's commonly upregulated in rheumatoid arthritis," said Yau, who provided bioinformatics expertise for much of TCGA's work over the past decade. "Perhaps we can repurpose drugs used to treat that non-malignant chronic disease, as researchers will now have the molecular rationale to explore this novel treatment strategy."

Even though TCGA is done—the database won't be added to or changed—this same kind of comprehensive and collaborative multi-platform genomic analysis continues nationwide under new NCI sponsorship. Stuart, Benz, and Yau continue to work together as part of their bioinformatic analysis center for the newly constituted Genomic Data Analysis Network which, among other challenges, is tasked with determining clinically measurable biomarkers that would make it easier and more cost effective to identify a priori those same molecular subsets identified by the TCGA network's multi-platform analysis.

"It's time to re-write the textbooks on cancer, and it's time to break down the silos in clinical oncology that make it difficult for patients to take advantage of this paradigm shift in cancer classification," said Benz.

Explore further: Cancer categories recast in largest-ever genomic study

More information: Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer, Cell (2018). DOI: 10.1016/j.cell.2018.03.022

An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics, Cell (2018). https://doi.org/10.1016/j.cell.2018.02.052

Related Stories

Cancer categories recast in largest-ever genomic study

August 7, 2014
New research partly led by UC San Francisco-affiliated scientists suggests that one in 10 cancer patients would be more accurately diagnosed if their tumors were defined by cellular and molecular criteria rather than by the ...

Pan-cancer studies find common patterns shared by different tumor types

September 26, 2013
Cancer encompasses a complex group of diseases traditionally defined by where in the body it originates, as in lung cancer or colon cancer. This framework for studying and treating cancer has made sense for generations, but ...

Novel classification can lead to new ways to diagnose and treat cancer

February 12, 2018
A novel approach to studying cancer has enabled researchers to group about 10,000 human cancers of 32 different types into 10 classes based on the molecular pathways that drive tumor growth. A better understanding of these ...

Prognostic role of elevated mir-24-3p in breast cancer

March 1, 2018
Despite improvements in local, regional and systemic therapies for breast cancer, 40,610 women are expected to die from metastatic breast cancer in the US in 2017.

Oncogenic signatures mapped in TCGA a guide for the development of personalized therapy

September 27, 2013
Clinical trial design for new cancer therapies has historically been focused on the tissue of origin of a tumor, but a paper from researchers at Memorial Sloan-Kettering Cancer Center published on September 26 in Nature Genetics ...

Tapping the genome's social network to find cancer drivers

December 5, 2017
Any one tumor might harbor mutations in thousands of different genes. The challenge is to find the driver mutations—which fuel cancerous activity, and might be promising treatment targets—within the haystack of passengers ...

Recommended for you

Aspirin could play valuable role as additional treatment for cancer

September 26, 2018
Regular use of aspirin could help in the treatment of some cancers, finds a new review of 71 medical studies.

Lung cancer drug could be repurposed to target 'zombie' proteins linked to leukemia

September 25, 2018
A new study by scientists at the University of Liverpool highlights how a clinically-approved lung cancer drug could potentially be 'repurposed' to design new treatments for future cancer therapies.

A protein called vaccinia-related kinase 1 may help cancer establish itself in new areas of the body during metastasis

September 25, 2018
Sometimes negative results can point researchers in the right direction.

Combo therapy of prostatectomy plus radiotherapy may improve survival in prostate cancer

September 25, 2018
High-risk prostate cancer, that which has continued to grow but not yet metastasized, is commonly treated with combination therapies. Each method has pros and cons, but there is little clarity whether one might be more effective ...

Brigatinib becomes potential new first-line option for ALK-positive non-small lung cancer

September 25, 2018
Results of a 275-patient, multi-national phase III clinical trial known as ALTA-1L published today in the New England Journal of Medicine and presented concurrently in the press program at the International Association for ...

Two studies describe improved approach to bone marrow transplant

September 25, 2018
Two recent studies in the journal Leukemia present a new approach for bone marrow donation and transplant that preclinical laboratory tests suggest could make the life-saving procedure safer and more effective for patients.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.